| Trial ID: | L5211 |
| Source ID: | NCT02518503
|
| Associated Drug: |
Rosuvastatin (≥10 Mg)
|
| Title: |
High Potency Statins and the Risk of Diabetes
|
| Acronym: |
Statins-DM
|
| Status: |
COMPLETED
|
| Study Results: |
NO
|
| Results: |
|
| Conditions: |
Diabetes Mellitus, Type 2|Cardiovascular Disease
|
| Interventions: |
DRUG: Rosuvastatin (≥10 mg)|DRUG: Atorvastatin (≥20 mg)|DRUG: Simvastatin (≥40 mg)|DRUG: Fluvastatin|DRUG: Pravastatin|DRUG: Lovastatin|DRUG: Rosuvastatin (<10mg)|DRUG: Atorvastatin (<20mg)|DRUG: Simvastatin (<40 mg)
|
| Outcome Measures: |
Primary: Number of participants with Incident type 2 diabetes, Patients with a first-hospitalization, receiving a principle or secondary diagnosis for diabetes (ICD-9: 250; ICD-10: E10, E11, E12, E13, E14), or a prescription for insulin or an oral antidiabetic medication., Patients will be followed from the date of study cohort entry until either hospitalization for diabetes or censoring (whichever occurs first), or will be assessed for up to 24 months. |
|
| Sponsor/Collaborators: |
Sponsor: Canadian Network for Observational Drug Effect Studies, CNODES | Collaborators: Drug Safety and Effectiveness Network, Canada|Canadian Institutes of Health Research (CIHR)
|
| Gender: |
ALL
|
| Age: |
ADULT, OLDER_ADULT
|
| Phases: |
|
| Enrollment: |
136966
|
| Study Type: |
OBSERVATIONAL
|
| Study Designs: |
Observational Model: |Time Perspective: p
|
| Start Date: |
2012-07
|
| Completion Date: |
2013-02
|
| Results First Posted: |
|
| Last Update Posted: |
2016-03-14
|
| Locations: |
|
| URL: |
https://clinicaltrials.gov/show/NCT02518503
|
